NovaBridge chair plans $5M ADS open-market buys

NovaBridge Biosciences reports that its Executive Chairman, Fu Wei, plans to purchase up to $5,000,000 of the company’s American depositary shares in open market transactions through an entity he controls.

Rhea-AI Filing Summary

NovaBridge Biosciences reports that its Executive Chairman, Fu Wei, plans to purchase up to $5,000,000 of the company’s American depositary shares in open market transactions through an entity he controls. The purchases began on January 15, 2026, but there is no assurance on how many ADSs will ultimately be bought or over what period, since execution depends on his decisions and market conditions.

Insights

Equity Market Analyst

Executive chairman plans open-market ADS purchases up to $5M.

The company discloses that Executive Chairman Fu Wei intends to buy up to $5,000,000 of NovaBridge Biosciences American depositary shares in open market transactions through a controlled entity. Such purchases can signal personal confidence but remain discretionary and are not a binding commitment to acquire a specific number of ADSs.

The disclosure notes that, although purchases started on January 15, 2026, there is no guarantee regarding the eventual amount or timing of transactions. Actual buying activity will depend on prevailing market conditions and Fu Wei’s decisions, so the real impact on trading volume or ownership structure is uncertain.

Because the plan is expressed as an intention and capped at an amount, its concrete significance will depend on how much of the $5,000,000 capacity is used over time and whether follow-up disclosures quantify completed purchases.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovaBridge Biosciences (NBP) disclose in this Form 6-K?

The report states that Executive Chairman Fu Wei intends to purchase up to $5,000,000 of NovaBridge Biosciences American depositary shares in open market transactions through an entity he controls.

How much NovaBridge Biosciences stock does Fu Wei plan to buy?

Fu Wei plans to buy up to $5,000,000 worth of NovaBridge Biosciences American depositary shares, according to the disclosure.

When did Fu Wei’s planned ADS purchases for NovaBridge (NBP) begin?

The open market purchases by Fu Wei’s controlled entity began on January 15, 2026, as described in the report.

Is NovaBridge Biosciences guaranteeing how many ADSs will be purchased?

No. The company explains it cannot guarantee the number of ADSs to be purchased or the time frame for the planned open market buying.

Is NovaBridge Biosciences itself repurchasing shares in this 6-K filing?

The filing describes planned open market purchases by Fu Wei via his controlled entity, not a direct share repurchase program by NovaBridge Biosciences.

Does the NovaBridge (NBP) 6-K include other business or clinical updates?

Beyond the planned ADS purchases and standard forward-looking statement language, the text focuses on cautionary risk factors related to the company’s drug development programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Fu Wei, the Executive Chairman of the Board of Directors of NovaBridge Biosciences (the “Company”), intends to purchase up to $5,000,000 of the Company’s American depositary shares (“ADSs”) in open market transactions. The purchases started on January 15, 2026. As the planned purchases are to be executed by Fu Wei via his controlled entity, the Company cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market.

Forward Looking Statements

This current report on Form 6-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential open market purchases by Fu Wei; the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates; the strategic and clinical development of the Company’s drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101; anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: prevailing market conditions; the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovaBridge Biosciences
	By	:	/s/ Xi-Yong Fu
	Name	:	Xi-Yong (Sean) Fu
	Title	:	Chief Executive Officer

Date: January 16, 2026